EMAIL THIS PAGE TO A FRIEND

Cancer immunology research

Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.


PMID 24778320

Abstract

Monocytes may contribute to tumor progression in part by mediating tumor-induced immunosuppression. Alterations to the monocyte populations and functions in untreated patients with late-stage melanoma are not fully understood. To characterize these alterations, we compared the frequency, phenotype, and functional capacity of peripheral blood monocytes and other myeloid cells in untreated, newly diagnosed stage IV melanoma patients (n = 18) with those in healthy volunteers. Stage IV untreated melanoma patients exhibited a sizeable decrease in the percentage of monocytes (P < 0.0001) that included a drop in the percentage of the CD14(+)CD16(-) classical monocyte pool (P = 0.006). Although there was not a significant difference in the CD14(+)HLA-DR(low/-) monocyte population between the patients with melanoma and the healthy volunteers, the HLA-DR levels were considerably lower in the patients' CD14(+)CD16(+) intermediate (P < 0.0001) and CD14(low)CD16(+) nonclassical monocyte populations (P = 0.001). Decreased surface expression of CD86 (P = 0.0006) and TNFRII (P = 0.0001) and increased expression of tissue factor and PD-L1 (P = 0.003) were identified on monocytes from patients with melanoma. Furthermore, these monocytes had decreased ability to upregulate CD80 expression and cytokine production following stimulation with agonist of Toll-like receptor 3 (TLR3). Peripheral blood dendritic cell subsets were decreased in untreated stage IV melanoma patients. Our study demonstrates that untreated late-stage melanoma patients exhibit monocytopenia in addition to phenotypic and functional deficiencies that may negatively affect their immune function. These findings open new avenues into examining the role of monocyte populations in melanoma development.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

GW23003 Anti-CD19 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB4700041 Anti-CD3, low endotoxin antibody, Mouse monoclonal, clone OKT3, purified immunoglobulin, buffered aqueous solution
SAB4300686
Anti-CD3E antibody produced in rabbit, affinity isolated antibody
SAB2502013
Anti-CD7 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405576
Anti-CD7 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1401056
Anti-CD7 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1406022
Anti-IL3RA antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA003539
Anti-IL3RA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2700234
Anti-Ncam1 (N-terminal) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2501672
Anti-NCAM1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB4300660
Anti-NCAM1 antibody produced in rabbit, affinity isolated antibody
SAB2501275
Anti-THY1 antibody produced in goat, affinity isolated antibody
HPA003733
Anti-THY1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4700268 Monoclonal Anti-CD16 antibody produced in mouse, clone MEM-168, purified immunoglobulin, buffered aqueous solution
SAB4700269 Monoclonal Anti-CD16 antibody produced in mouse, clone LNK16, purified immunoglobulin, buffered aqueous solution
SAB4700274 Monoclonal Anti-CD16 antibody produced in mouse, clone 3G8, purified immunoglobulin, buffered aqueous solution
SAB4700276 Monoclonal Anti-CD16 antibody produced in mouse, clone MEM-154, purified immunoglobulin, buffered aqueous solution
WH0000930M1
Monoclonal Anti-CD19 antibody produced in mouse, clone 1G3, purified immunoglobulin, buffered aqueous solution
SAB1403645
Monoclonal Anti-CD19 antibody produced in mouse, clone 1C9, purified immunoglobulin, buffered aqueous solution
SAB4700108 Monoclonal Anti-CD19 antibody produced in mouse, clone 4G7, purified immunoglobulin, buffered aqueous solution
SAB4700109 Monoclonal Anti-CD19 antibody produced in mouse, clone LT19, purified immunoglobulin, buffered aqueous solution
C7048
Monoclonal Anti-CD3 antibody produced in mouse, clone UCHT-1, purified immunoglobulin, buffered aqueous solution
SAB4700040 Monoclonal Anti-CD3 antibody produced in mouse, clone OKT3, purified immunoglobulin, buffered aqueous solution
SAB4700044 Monoclonal Anti-CD3 antibody produced in mouse, clone MEM-57, purified immunoglobulin, buffered aqueous solution
SAB4700045 Monoclonal Anti-CD3 antibody produced in mouse, clone MEM-92, purified immunoglobulin, buffered aqueous solution
SAB4700050 Monoclonal Anti-CD3 antibody produced in mouse, clone APA1/1, purified immunoglobulin, buffered aqueous solution
WH0000916M4
Monoclonal Anti-CD3E antibody produced in mouse, clone 4C1, purified immunoglobulin, buffered aqueous solution
AMAB90876
Monoclonal Anti-CD3E antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1466, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90879
Monoclonal Anti-CD3E antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1497, purified immunoglobulin, buffered aqueous glycerol solution
SAB4700449 Monoclonal Anti-CD56 antibody produced in mouse, clone MEM-188, purified immunoglobulin, buffered aqueous solution